Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | VDR | P11473 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496757 | 0.83 | — | — | |
| SCHEMBL10019280 | 0.80 | MAPK1 (0.42) | MAPK1SMN1; SMN2HTTALDH1A1VDR | |
| SCHEMBL18651063 | 0.80 | MAPK1 (0.42) | MAPK1SMN1; SMN2HTTALDH1A1KDM4E | |
| SCHEMBL10051165 | 0.78 | MAPK1 (0.41) | MAPK1SMN1; SMN2HTTALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL23467006 | 0.77 | MAPK1 (0.43) | MAPK1SMN1; SMN2HTTALDH1A1VDR | |
| SCHEMBL5579311 | 0.76 | ALDH1A1 (0.46) | MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12914639 | 0.76 | DGAT1 (0.35) | HTTPKMKDM4E | |
| SCHEMBL25604269 | 0.75 | HTT (0.39) | HTTPKMKDM4E | |
| SCHEMBL13141065 | 0.75 | TSHR (0.38) | HTTALDH1A1PKMKDM4E | |
| SCHEMBL11340608 | 0.74 | POLB (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104350-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | MAPK1 754/4885SMN1; SMN2 3728/4885HTT 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.